The Effect of Polycystic Ovary Syndrome on Pelvic Floor Structure and Function

Study Overview
=================
Brief Summary
-----------------
Polycystic Ovarian Syndrome (PCOS) is the most common endocrinological disorder in women of reproductive age, and its prevalence is reported to be 6-21% in women aged 15-49 (1). Although its etiopathogenesis is still not clear, it is known that it is due to the disregulation of ovarian steroidogenesis under the influence of some environmental and genetic factors. Diagnosis of ESHRE / ASRM has set Rotterdam criteria in 2003; one of these criteria is the presence of hyperandrogenism (2). Hyperandrogenism leads to an increase in general muscle mass in the body (1, 3, 4). Pelvic floor muscles are associated with urethra in the anterior compartment, rectum and anus in the posterior compartment, and uterine support in the apex; major urinary and fecal continence ensuring its functions in order to stop in the appropriate position of the pelvic organs (5). The well-being of the pelvic floor muscle strength has a protective effect from urinary and fecal incontinence. It has been emphasized that the anogenital distance determined by the measurement of the anal region anterior to the clitoris anterior may also be a criteria in the diagnosis of Polycystic Ovary Syndrome (7,8,9). In this study, patients in the reproductive age between 18-40 years, who applied to our gynecology outpatient clinic and were diagnosed as PCOS according to Rotterdam criteria wil be study gorup and the women without PCOS will be control group. We aimed to evaluate the pelvic muscle strength with perineometry, to measure anogenital distance and to determine possible relationships with each other. In addition to demographic information, ICIQ-SF (Urinary incontinence inquiry short form) will also be taken to evaluate pelvic floor function (10).

Official Title
-----------------
The Effect of Polycystic Ovary Syndrome on Pelvic Floor Structure and Function

Conditions
-----------------
Reproductive System Disorder, Urinary Incontinence, Urogenital Disease, Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Anogenital distance measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nulliparity Exclusion Criteria: Endocrine disorders Anabolic drug usage Multiparity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group 1<br>Hiperandrogenism + ultrasonographic PCO | Diagnostic Test: Anogenital distance measurement<br>* Measurements of AGD and perineal muscle strength<br>|
| Study group 2<br>Menstruel cycle irregular + ultrasonographic PCO | Diagnostic Test: Anogenital distance measurement<br>* Measurements of AGD and perineal muscle strength<br>|
| Study group 3<br>Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism | Diagnostic Test: Anogenital distance measurement<br>* Measurements of AGD and perineal muscle strength<br>|
| Control group<br>Do not have PCOS | Diagnostic Test: Anogenital distance measurement<br>* Measurements of AGD and perineal muscle strength<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anogenital distance measurement in PCOS |  | 01.06.2020- 01.11.2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polycystic ovary syndrome, urinary incontinence, anogenital distance